Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?

Basit Öğe Kaydı
dc.contributor.authorGüliter S.
dc.contributor.authorKeleş H.
dc.contributor.authorÖzkurt Z.N.
dc.contributor.authorCengiz D.U.
dc.contributor.authorKolukisa E.
dc.date.accessioned2020-06-25T15:13:33Z
dc.date.available2020-06-25T15:13:33Z
dc.date.issued2005
dc.departmentKırıkkale Üniversitesi
dc.description.abstractBackground/aims: To determine H. pylori eradication rate with lansoprazole-amoxicillin-clarithromycin treatment regimen, which is the most frequently used as first-line therapy, in the Kirikkale region. Methods: One hundred and five patients (44 male, 61 female) with H. pylori infection were included in the study. Patients were divided into two groups based on the endoscopic findings: non-ulcer dyspepsia (n=84, 31 male, 53 female) and acute gastric or duodenal ulcer (n=21, 13 male, 8 female) groups. The diagnosis of H. pylori infection was confirmed if both the urease test and histological examination, which were performed on endoscopic biopsies, were positive. Lansoprazole 30 mg, amoxicillin 1 g, and clarithromycin 500 mg were given twice daily for 14 days to all patients. Endoscopic biopsies were repeated for the evaluation of eradication three months after the treatment. Results: Ninety-six patients completed the study. Eradication rates were found to be 45.8% (44 of 96) in all patients, 42.1% (32 of 76 patients) in the non-ulcer dyspepsia group and 60% (12 of 20 patients) in the gastric or duodenal ulcer group for per protocol analysis, and the difference between non-ulcer dyspepsia and gastric or duodenal ulcer groups was not statistically significant (p=0.208). Conclusions: Lansoprazole-amoxicillin-clarithromycin treatment regimen, the most frequently preferred regimen in H. pylori eradication, is ineffective in our region. The low eradication rates observed with lansoprazole-amoxicillin-clarithromycin, at least in our region, bring into question its use as a first-line therapy. The use of alternative treatment protocols or antibiotic susceptibility test before the treatment may be helpful in achieving successful eradication with first-line therapy.en_US
dc.identifier.citationGüliter, S., Keleş, H., Özkurt, Z. N., Cengiz, D. U., Kolukısa, E. (2005). Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?. Turkish Journal of Gastroenterology, 16(1), 29 - 33.en_US
dc.identifier.endpage33en_US
dc.identifier.issn13004948
dc.identifier.issue1en_US
dc.identifier.pmid16252185
dc.identifier.scopus2-s2.0-17644416776
dc.identifier.scopusqualityQ3
dc.identifier.startpage29en_US
dc.identifier.trdizinid49286
dc.identifier.urihttps://hdl.handle.net/20.500.12587/1844
dc.identifier.volume16en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.relation.ispartofTurkish Journal of Gastroenterology
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAmoxicillinen_US
dc.subjectClarithromycinen_US
dc.subjectHelicobacter pylori eradicationen_US
dc.subjectLansoprazoleen_US
dc.titleCan lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?en_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
525bcd1e-19e7-40d9-868b-b631c0610885.pdf
Boyut:
469.15 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/Full text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu